Literature DB >> 22198048

Patients with atypical hyperplasia of the endometrium should be treated in oncological centers.

Sofie Leisby Antonsen1, Lian Ulrich, Claus Høgdall.   

Abstract

OBJECTIVES: To examine the prevalence of undiagnosed endometrial carcinoma (EC) among women with a preoperative diagnosis of atypical endometrial hyperplasia (AEH) in correlation to age, BMI and menopause.
METHODS: Data extracted from the Danish Gynecological Cancer Database (DGCD) covering women diagnosed with AEH between January 1, 2005 and November 1, 2010 undergoing surgery. DGCD is a multidisciplinary, nationwide, clinical database of all cases of gynecological cancer and AEH in Denmark diagnosed after January 1, 2005. Registration is mandatory. Primary outcome was preoperative- and postoperative diagnoses. Secondary outcomes were relationship to BMI, age and menopause.
RESULTS: The preoperative diagnosis of AEH was retained in 41% of 773 cases and 59% had endometrial cancer. Of the cancer cases, 18% had more than Stage I disease and 3% were non-endometrioid. Cancer risk was significantly related to age (p<0.0001) and menopause (p<0.0001). The 80% who were postmenopausal had a significantly higher risk of a postoperative cancer diagnosis compared with the premenopausal group (OR 2.8). There was no significant difference regarding BMI (p=0.25).
CONCLUSION: More than half of the 773 Danish women primarily diagnosed with AEH had undiagnosed cancer. Failure to diagnose endometrial carcinoma preoperatively can lead to inadequate staging and potentially suboptimal treatment. We recommend that atypical endometrial hyperplasia should be treated as carcinoma in specialized gynecological-oncology centers. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22198048     DOI: 10.1016/j.ygyno.2011.12.436

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  New WHO Classification of Endometrial Hyperplasias.

Authors:  G Emons; M W Beckmann; D Schmidt; P Mallmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-02       Impact factor: 2.915

2.  Endometrial Cancer Incidence in Patients With Atypical Endometrial Hyperplasia According to Mode of Management.

Authors:  Anas Barakat; Aemn Ismail; Supratik Chattopadhyay; Quentin Davies
Journal:  Cancer Diagn Progn       Date:  2022-09-03

3.  Fertility-Sparing Treatment for Atypical Endometrial Hyperplasia and Endometrial Cancer: A Cochrane Systematic Review Protocol.

Authors:  Maria-Eulalia Fernandez-Montoli; Jordi Sabadell; Nayanar-Adela Contreras-Perez
Journal:  Adv Ther       Date:  2021-04-08       Impact factor: 3.845

4.  Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.

Authors:  Anna Berg; Erling A Hoivik; Siv Mjøs; Frederik Holst; Henrica M J Werner; Ingvild L Tangen; Amaro Taylor-Weiner; William J Gibson; Kanthida Kusonmano; Elisabeth Wik; Jone Trovik; Mari K Halle; Anne M Øyan; Karl-Henning Kalland; Andrew D Cherniack; Rameen Beroukhim; Ingunn Stefansson; Gordon B Mills; Camilla Krakstad; Helga B Salvesen
Journal:  Oncotarget       Date:  2015-01-20

5.  Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer.

Authors:  Josef Chovanec; Iveta Selingerova; Kristina Greplova; Sofie Leisby Antonsen; Monika Nalezinska; Claus Høgdall; Estrid Høgdall; Erik Søgaard-Andersen; Kirsten M Jochumsen; Pavel Fabian; Dalibor Valik; Lenka Zdrazilova-Dubska
Journal:  Oncotarget       Date:  2017-11-21

6.  Sentinel lymph node mapping using indocyanine green in patients with uterine and cervical neoplasms: restrictions of the method.

Authors:  M Bedyńska; G Szewczyk; T Klepacka; K Sachadel; T Maciejewski; D Szukiewicz; A Fijałkowska
Journal:  Arch Gynecol Obstet       Date:  2019-02-14       Impact factor: 2.344

7.  Risk factors of progression to endometrial cancer in women with endometrial hyperplasia: A retrospective cohort study.

Authors:  Jin Young Jeong; Sung Ook Hwang; Banghyun Lee; Kidong Kim; Yong Beom Kim; Sung Hye Park; Hwa Yeon Choi
Journal:  PLoS One       Date:  2020-12-01       Impact factor: 3.240

8.  Lymph node dissection in atypical endometrial hyperplasia.

Authors:  Salih Taşkın; Özgür Kan; Ömer Dai; Elif A Taşkın; Kazibe Koyuncu; Ayşegül Alkılıç; Mete Güngör; Fırat Ortaç
Journal:  J Turk Ger Gynecol Assoc       Date:  2017-09-01

9.  Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers.

Authors:  Ingfrid S Haldorsen; Camilla Krakstad; Anna Berg; Ankush Gulati; Sigmund Ytre-Hauge; Kristine E Fasmer; Karen K Mauland; Erling A Hoivik; Jenny A Husby; Ingvild L Tangen; Jone Trovik; Mari K Halle; Ingunn Stefansson; Lars A Akslen; Kathrine Woie; Line Bjørge; Helga B Salvesen; Øyvind O Salvesen; Henrica M J Werner
Journal:  Oncotarget       Date:  2017-07-31

10.  Menopausal Status Combined with Serum CA125 Level Significantly Predicted Concurrent Endometrial Cancer in Women Diagnosed with Atypical Endometrial Hyperplasia before Surgery .

Authors:  Yaochen Lou; Jiongbo Liao; Weiwei Shan; Zhiying Xu; Xiaojun Chen; Jun Guan
Journal:  Diagnostics (Basel)       Date:  2021-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.